Clinical Trial Update: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, pharmacokinetics, and efficacy of EDP-305 in subjects with primary biliary cholangitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• EDP-305

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: Primary Biliary Cholangitis | Phase 2 | Status: COMPLETED | Results posted: 2021-05-18